论文部分内容阅读
目的:探讨非布司他对痛风合并高尿酸血症患者血清内皮素-1(ET-1)、细胞间粘附分子-1(ICAM-1)及尿酸水平的影响。方法:收集在我院就诊或住院治疗的80例痛风合并高尿酸血症患者,随机分为实验组和对照组,每组40例。对照组患者给予别嘌呤醇片治疗;实验组患者给予非布司他片治疗。观察并比较两组患者治疗前后血尿酸、s ICAM-1、ET-1水平及临床疗效。结果:与治疗前相比,两组患者治疗后的血尿酸、s ICAM-1、ET-1水平均显著降低(P<0.05);与对照组相比,实验组患者的血尿酸、s ICAM-1、ET-1水平较低(P<0.05),临床治疗总有效率较高(P<0.05)。结论:非布司他能够降低痛风合并高尿酸血症的s ICAM-1、ET-1及尿酸水平,且临床疗效较好。
Objective: To investigate the effects of febuxostat on serum endothelin-1 (ET-1), intercellular adhesion molecule-1 (ICAM-1) and uric acid in patients with gout and hyperuricemia. Methods: 80 cases of gout combined with hyperuricemia were collected in our hospital for treatment or hospitalization, and randomly divided into experimental group and control group, 40 cases in each group. Patients in the control group were treated with allopurinol tablets; patients in the experimental group were treated with febuxostat. The levels of serum uric acid, s ICAM-1 and ET-1 in two groups before and after treatment were observed and compared. Results: The levels of serum uric acid, s ICAM-1 and ET-1 after treatment in both groups were significantly lower than those before treatment (P <0.05). Compared with the control group, the levels of serum uric acid, s ICAM -1, ET-1 level was lower (P <0.05), and the total effective rate of clinical treatment was higher (P <0.05). Conclusion: Febu Bostat can reduce the levels of s ICAM-1, ET-1 and uric acid in patients with gout and hyperuricemia with good clinical efficacy.